INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2012

Pre-diagnostic biomarkers of acrylamide exposure were linked to higher breast cancer-specific mortality among non-smoking postmenopausal Danish women.

Researchers evaluated whether pre-diagnostic acrylamide exposure, measured via acrylamide and glycidamide hemoglobin adducts (AA-Hb and GA-Hb), was associated with mortality in 420 postmenopausal women who developed breast cancer. Blood samples were analyzed using Cox proportional hazard models. Among non-smokers, higher GA-Hb levels per 25 pmol/g globin were associated with higher breast cancer-specific mortality (HR: 1.63, 95% CI: 1.06-2.51), reaching an HR of 2.23 (95% CI: 1.38-3.61) among those with estrogen receptor-positive tumors. For AA-Hb, higher levels were statistically significantly associated with mortality among women with estrogen receptor-positive tumors (HR: 1.31, 95% CI: 1.02-1.69).

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
420 postmenopausal Danish women with breast cancer (from a cohort of 24,697)
What was measured
Mortality after breast cancer diagnosis

THE PAPER

Pre-diagnostic acrylamide exposure and survival after breast cancer among postmenopausal Danish women.

Olsen A, Christensen J, Outzen M, Olesen PT, Frandsen H, Overvad K, Halkjær J. Toxicology, 2012.

PubMed 22465873 ↗DOI 10.1016/j.tox.2012.03.004 ↗

CancerFood safety & contaminants

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.